Showing results (111-120 of 135) with videos related to
Sort By:
Pageof 14
Annals of Surgery|July 12, 2018
Morphological Factors Related to Nodal Metastases in Neuroendocrine Tumors of the Appendix: A Multicentric Retrospective StudyNicole Brighi, Stefano La Rosa, Giulio Rossi, et al.JTO Clinical and Research Reports|September 30, 2021
Association Between Immune-Related Adverse Events and Clinical Outcomes to Programmed Cell Death Protein 1/Programmed Death-Ligand 1 Blockade in SCLCBiagio Ricciuti, Abdul Rafeh Naqash, Jarushka Naidoo, et al.Frontiers in Microbiology|August 15, 2022
Dynamics of Viral Infection and Evolution of SARS-CoV-2 Variants in the Calabria Area of Southern ItalyCarmela De Marco, Claudia Veneziano, Alice Massacci, et al.Journal for Immunotherapy of Cancer|July 24, 2023
Efficacy of PD-(L)1 blockade monotherapy compared with PD-(L)1 blockade plus chemotherapy in first-line PD-L1-positive advanced lung adenocarcinomas: a cohort studyArielle Elkrief, Joao M Victor Alessi, Biagio Ricciuti, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|April 18, 2025
Factors Associated with Disease Progression after Discontinuation of Immune Checkpoint Inhibitors for Immune-Related Toxicity in Patients with Advanced Non-Small Cell Lung CancerFederica Pecci, Rohit Thummalapalli, Stephanie L Alden, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 9, 2020
Molecular Mechanisms of Acquired Resistance to MET Tyrosine Kinase Inhibitors in Patients with MET Exon 14-Mutant NSCLCGonzalo Recondo, Magda Bahcall, Liam F Spurr, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 12, 2023
Clinicopathologic and Genomic Factors Impacting Efficacy of First-Line Chemoimmunotherapy in Advanced NSCLCJoao V Alessi, Arielle Elkrief, Biagio Ricciuti, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 11, 2023
Clinical and Molecular Features of Long-term Response to Immune Checkpoint Inhibitors in Patients with Advanced Non-Small Cell Lung CancerRohit Thummalapalli, Biagio Ricciuti, Chaitanya Bandlamudi, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 5, 2019
Immune Checkpoint Inhibitor Therapy in Patients With Preexisting Inflammatory Bowel DiseaseHamzah Abu-Sbeih, David M Faleck, Biagio Ricciuti, et al.JTO Clinical and Research Reports|October 14, 2024
Three-Year Overall Survival Outcomes and Correlative Analyses in Patients With NSCLC and High (50%-89%) Versus Very High (≥90%) Programmed Death-Ligand 1 Expression Treated With First-Line Pembrolizumab or CemiplimabBiagio Ricciuti, Arielle Elkrief, Jessica Lin, et al.Pageof 14